Gene Name Synonym

TNF-alpha, TNFα, DIF, TNFA, TNFSF2, cachexin, cachectin

Species

Human

Accession

P01375

Source

HEK293 cells

SPECIFICATIONS

Amino acid sequence

Val77-Leu233 is expressed with a 10×His tag at the N terminus

Molecular Weight

18.8 kDa

Purity

>95.0% as determined by SDS-PAGE

Endotoxin

<5 EU mg^-1

Formulation

Lyophilized from sterile PBS, pH 7.4.Normally 5%-8% trehalose and mannitol are added as protectants before lyophilization.

Reconstitution

Dissolved in sterile water, it is recommended to add 0.1% HSA or BSA for long-term preservation.

STORAGE

Stability and Storage

12 months from date of receipt at -20°C to -70°C. After reconstitution, it is stable at 4°C for 1 week or -20°C for almost 6 months (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

BACKGROUND

Tumor necrosis factor alpha (TNF-alpha ), also known as cachectin and TNFSF2, is the prototypic ligand of the TNF superfamily. It is a pleiotropic molecule that plays a central role in cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. TNF-alpha binds the ubiquitous 55-60 kDa TNF RI and the hematopoietic cell-restricted 80 kDa TNF RII, both of which are also expressed as homotrimers. Both type I and type II receptors bind TNF-alpha with comparable affinity, although only TNF RI contains a cytoplasmic death domain which triggers the activation of apoptosis. Soluble forms of both types of receptors are released and can neutralize the biological activity of TNF-alpha. TNF-alpha protein is produced mainly by macrophages, and large amounts of this cytokine are released in response to lipopolysaccharide, other bacterial products, and Interleukin-1 (IL-1). TNF-alpha is involved in fighting against the tumorigenesis, thus, is regarded as a molecular insight in cancer treatment.

Data

SDS-PAGE

Bioactivity

Active Recombinant Human TNF-alpha Protein was determined by SDS-PAGE with Coomassie Blue.

Measured in a cytotoxicity assay using L929 mouse fibrosarcoma cells in the presence of the metabolic inhibitor actinomycin D. The ED50 for this effect is typically 0.1-0.5 ng/mL.